9 January 2024 - SER-155 Phase 1b placebo controlled Cohort 2 data readout anticipated in third quarter of 2024.

SER-155 builds upon the clinical success of Vowst and is an investigational oral, cultivated microbiome therapeutic designed to prevent GI associated bacterial infections, including blood stream infections, and to reduce the incidence of severe acute graft versus host disease in immunocompromised patients undergoing allogeneic haematopoietic stem cell transplantation.

Read Seres Therapeutics press release